FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology and may be used for the purpose of treating a patient with secondary bone tumour. That is ensured by introducing an antibody or a fragment thereof specific for human PDGFRα.
EFFECT: invention provides neutralising PDGFRα activation that leads to the inhibition of tumour cell mobility, prevents metastasing.
5 cl, 20 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECEPTOR ANTAGONISTS FOR TREATING METASTATIC CANCER | 2009 |
|
RU2455026C2 |
| HUMAN ANTIBODIES TO RECEPTOR OF EPIDERMAL GROWTH FACTOR | 2005 |
|
RU2402569C2 |
| HYBRID PROTEINS BASED ON HUMAN Notch3 AS TRAPS-INHIBITORS OF Notch3 SIGNAL TRANSMISSION | 2009 |
|
RU2567662C2 |
| GROWTH HORMONE RECEPTOR BLOCKERS FOR DISEASE PREVENTION AND TREATMENT | 2016 |
|
RU2726254C2 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| METHOD FOR RECEPTOR TYROSINE KINASE INHIBITION WITH USE EXTRACELLULAR ANTAGONIST AND INTRACELLULAR ANTAGONIST | 2004 |
|
RU2431500C2 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| METHODS FOR BONE CANCER RELATED PAIN MANAGEMENT BY ADMINISTRATION OF NERVE GROWTH FACTOR ANTAGONIST | 2005 |
|
RU2389509C2 |
| RECEPTOR IGF-I ANTIBODIES | 2003 |
|
RU2421465C2 |
